MeiraGTx Brings Rare Eye Disease Gene Therapy Back Home
Deal Snapshot: Despite missing its primary goal in a Phase III trial, MeiraGTx intends to move quickly towards global regulatory submissions for the XLRP gene therapy bota-vec which it has reacquired from long-time partner J&J.
Scrip - April 17, 2026

Lupin Follows Sandoz, Sun In Antitrust Suit Settlement; $30m For Humana
Lupin has followed Sandoz and Sun Pharma in settling antitrust litigation on alleged price-fixing. This $30m settlement with US insurance giant Humana denies all allegations and does not imply admission of liability, but could more settlements be in the offing?
Scrip - April 17, 2026

Freya Lines Up FB301 Phase II Push After Promising Early Stage Data
The firm's microbiome-based therapy is poised for Phase II development as it targets a market with limited treatment options.
Scrip - April 17, 2026

Japan Q1 Roundup Podcast: Iran War Impact, Divestments, Product Approvals
Join our Japan-based team for an audio roundup of key developments in the country's biopharma industry over the first few months of this year.
Scrip - April 17, 2026

Northern Ireland Devices To Use EUDAMED In May
UK MHRA reminds NI device registrants about compulsory use of EUDAMED system from May 28.
Medtech Insight - April 17, 2026

Former CDRH Diagnostics Lead, Deputy FDA Commissioner Tapped For HHS Senior Counselor Role
President Trump announced Sara Brenner’s appointment along with his nominee for Centers for Disease Control and Prevention director.
Medtech Insight - April 17, 2026

US Consumer Health Executive Moves: CRN/Radicle Award, Designs For Health, Gimme Seaweed, More
Annette Dickinson Trailblazer Award nominations open; Designs for Health names EO, founder moves to chair; Gimmee Seaweed names CEO, Ad Agency; and interim CFO at Mannatech.
HBW Insight - April 17, 2026

PAGB Hosts Swedish Delegation To Share Rx-to-OTC And Prevention Best Practice
A high-level delegation from Sweden is visiting the UK to discuss Rx-to-OTC switch and pharmacy-led healthcare.
HBW Insight - April 17, 2026

Hikma Hits Back Over Amarin’s ‘Strawman’ Induced Infringement Claims
As Amarin and Hikma continue to file briefs with the Supreme Court ahead of oral arguments at the end of this month in their skinny-label induced-infringement litigation over carve-outs for generic Vascepa (icosapent ethyl), the latest development sees Hikma attacking Amarin’s 'safe harbor' claims.
Generics Bulletin - April 17, 2026

Mabwell Finds A Denosumab Biosimilar Partner In Malaysia
Mabwell has signed a Malaysian licensing deal for its denosumab biosimilars Mailishu and Maiweijian, further expanding its footprint in Southeast Asia.
Generics Bulletin - April 17, 2026

Amneal Builds Scale In US Drug-Device Respiratory Market
Amneal has launched its first US metered-dose inhalers, introducing generics to ProAir and legacy QVAR products as legal wins, patent scrutiny, and regulatory shifts further open a long-protected respiratory market.
Generics Bulletin - April 17, 2026

Mochida Chases Gap In Japanese IVF Biosimilars
Mochida has partnered with Qilu Pharmaceutical to develop and commercialize a follitropin alfa IVF biosimilar in Japan, marking its entry into reproductive medicine biosimilars and targeting an underpenetrated but growing fertility market.
Generics Bulletin - April 17, 2026

Healthtech Start-Ups Set The Tone At BioWales ’26
A “venture builder” in precision mental health biology, a company that has done the heavy lifting for a class III cardiac implantable and a diagnostics innovator addressing care shift realities long before the NHS’s 10-Year Plan was issued were among the start-ups seeking investors at BioWales 2026.
In Vivo - April 15, 2026

How An Italian Ocular AAV Innovator Is Bucking The Trend In Gene Therapy
AAVantgarde is advancing dual-AAV gene therapies for two inherited retinal diseases, using staged clinical de-risking to build investor and regulatory confidence ahead of key 2026 data readouts.
In Vivo - April 15, 2026

Rising Leaders: Helping AI Software Enter Healthcare Systems And Markets
Isabel Vincent, market development manager at life sciences software consultancy Firefinch, has seen an explosion in workload as healthcare organizations and healthtech innovators embed new functionalities into businesses processes. Away from that job, she finds time to advise and mentor start-ups.
In Vivo - April 15, 2026